Harry L.A. Janssen, M.D., Ph.D., Hendrik W. Reesink, M.D., Ph.D., Eric J. Lawitz, M.D., Stefan Zeuzem, M.D., Maribel Rodriguez-Torres, M.D., Keyur Patel, M.D., Adriaan J. Van der Meer, M.D., Amy K. Patick, Ph.D., Alice Chen, B.A., Yi Zhou, Ph.D., Robert Persson, Ph.D., Barney D. King, M.D., Sakari Kauppinen, Ph.D., Arthur A. Levin, Ph.D., and Michael R. Hodges, M.D.: Treatment of HCV Infection by Targeting MicroRNA Around 170 million persons worldwide are chronically infected with the hepatitis C virus .1 Chronic HCV infection is a significant reason behind liver cirrhosis, liver failure, and hepatocellular carcinoma and may be the leading indication for liver transplantation in many Western countries.2 Sustained eradication of HCV infection has been associated with a reduced risk of liver-related morbidity and all-cause mortality.3-5 Despite the recent registration of protease inhibitors for the treating chronic HCV genotype 1 infection, current therapeutic regimens remain reliant on the administration of pegylated interferon and ribavirin for 24 to 48 weeks.6,7 Thus, anti-HCV therapy continues to be associated with substantial unwanted effects.All episodes happened at least four weeks after vaccination.19). All strains were found to express Vi capsular polysaccharide. None of the a priori subgroup analyses revealed significant distinctions in vaccine safety according to subgroup.).47) in the adjusted analysis. Overall and Indirect Protection Within an adjusted model, the Vi vaccine supplied significant indirect protection against typhoid fever among unvaccinated residents in Vi vaccine clusters, with a level of protective performance of 44 percent .